All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

IMPROVE: Continued BTKi use vs a 3-week pause before COVID-19 vaccination in CLL

By Sheetal Bhurke

Share:

Jul 7, 2025

Learning objective: After reading this article, learners will be able to cite a new clinical development in chronic lymphocytic leukemia.



While BTKis have revolutionized CLL management, they are associated with impaired vaccine-induced immunity. Observational data indicate that immunity may be improved by a short pause in BTKi treatment around the time of vaccination. However, this approach has not been evaluated in prospective studies, leading to conflicting recommendations regarding the use of BTKis.

Cook et al. conducted a two-arm, parallel-group, superiority, randomized controlled trial (IMPROVE, ISRCTN 14197181), which enrolled patients with CLL across 11 UK hematology clinics to evaluate the impact on antibody responses of continuous BTKi use vs a 3-week BTKi pause. Findings were published in The Lancet Hematology.1

Eligible patients (N = 99) with a diagnosis of CLL who had been on either ibrutinib or acalabrutinib for at least 12 months were randomized 1:1 to receive continuous BTKi (n = 49) or to have a 3-week pause (n = 50). The primary outcome measure was RBD antibody titers 3 weeks after SARS-CoV-2 booster vaccination. Key secondary outcomes included RBD titers at 12 weeks and safety.

Key learnings

At 3 weeks, the geometric mean RBD antibody titer was 218.8 U/mL in the continue group vs 153.4 U/mL in the pause group (GMR 1.104; 95% CI, 0.565–2.158; p = 0.770). 

No difference in RBD antibody titer was observed between the continue group (177.6 U/mL) and the pause group (122.4 U/mL) at 12 weeks (GMR 1.037; 95% CI, 0.529–2.035; p = 0.91).

At 12 weeks, one participant reported lymphadenopathy in the pause group vs no reports of lymphadenopathy in the continue group. While there were no hospital admissions reported, one participant in the pause group died due to COVID-19 infection.

This trial found no benefit from pausing BTKi therapy during SARS-CoV-2 booster vaccination in patients with CLL and suggests that a pause should not be recommended to enhance immunity during vaccination in clinical practice. 

BTKi, Bruton’s tyrosine kinase inhibitor; CI, confidence interval; CLL, chronic lymphocytic leukemia; GMR, geometric mean ratio; RBD, receptor binding domain; SARs-CoV-2, severe acute respiratory syndrome coronavirus 2.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?